# TAC01-CLDN18.2

Source: https://onco.cc/drugs/tac01-cldn18-2/  
OnCo record `tac01-cldn18-2` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TAC01-CLDN18.2 is an experimental TCR-T cell therapy from Triumvira Immunologics in phase 2 trials, aimed at Claudin 18.2.

## Summary

TAC01-CLDN18.2 (TAC01) is a TCR-T cell therapy developed by Triumvira Immunologics. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: A genetically engineered autologous T-cell therapy using a T-cell receptor Antigen Coupler (TAC) that directs T cells to CLDN18.2-expressing tumour cells and, once engaged, activates the T cells via the endogenous T-cell receptor. ClinicalTrials.gov describes the intervention as: TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05862324, plans to enrol 113 participants with primary completion expected 2027-08-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: TAC01
- Modality: TCR-T cell therapy
- Mechanism: A genetically engineered autologous T-cell therapy using a T-cell receptor Antigen Coupler (TAC) that directs T cells to CLDN18.2-expressing tumour cells and, once engaged, activates the T cells via the endogenous T-cell receptor.

## Sources

- ClinicalTrials.gov: trials of TAC01-CLDN18.2: https://clinicaltrials.gov/search?intr=TAC01

## Connected records

- technologies: [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [Triumvira Immunologics](https://onco.cc/companies/triumvira-immunologics/)
- trials: [TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)](https://onco.cc/trials/nct05862324/)

---
JSON: https://onco.cc/api/v1/entities/tac01-cldn18-2.json